Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

prescription medicines

Deal Watch December 2016

Allergan, AZ, BMS, Pfizer, Roche and more feature in this month's pharma deals round-up

AstraZeneca AZ

AZ tweaks immuno-oncology trials as it chases lung cancer leaders

Toughens targets for durvalumab in NSCLC monotherapy and combination study

- PMLiVE

Merck & Co’s Keytruda muscles further ahead of rivals in lung cancer

Granted accelerated review by FDA for use in combination with chemotherapy

- PMLiVE

AstraZeneca appoints head of oncology

Dr Jamie Freedman joins from AZ subsidiary MedImmune

- PMLiVE

Sanofi and Boehringer Ingelheim complete €21.8bn asset swap

Exchange of animal health and consumer interests sharpens the firm's focus

- PMLiVE

GSK targets COPD adherence with integrated inhaler sensors

Hopes real-time patient experience data will improve clinical trial engagement

- PMLiVE

FDA okays Clovis’ Lynparza rival rucaparib

Analysts predict Rubraca could become a $1.5bn-plus product by 2020

Sanofi reception

Lilly and Boehringer launch first Lantus clone Basaglar in US

Starts biosimilar at 15% discount to Sanofi’s basal insulin product

Eli Lilly HQ

Lilly taps AstraZeneca for another anti-amyloid drug

MEDI1814 could potentially slow the progression of Alzheimer's

- PMLiVE

AZ’s Tagrisso beats chemotherapy in lung cancer trial

Phase III data shows greater progression-free survival in mutation-positive NSCLC patients

- PMLiVE

New Jardiance label could boost sales by $1.7bn, says analyst

Diabetes treatment can reduce the risk of cardiovascular death in type 2 patients

AstraZeneca AZ

AZ signs $1bn deal with Bicycle Therapeutics

Eyes broad range of applications for the firm’s peptide technology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links